Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in COVID-19 Patients With and Without Breast Cancer
NCT04871854Phase 2Completed
- Sponsor
- Beni Suef University
- Start
- Apr 2021
- Primary completion
- Jul 2022
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in coronavirus disease 2019 (COVID-19), sponsored by Beni Suef University. Started Apr 2021; status: completed.
02
Drugs
tocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04871854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04871854.